Commenting period (July 15, 2023 21:12 – August 16, 2023 00:00) is closed
ALS-19-v1
0 General Document comments
0 Sentence and Paragraph comments
0 Image and Video comments
1 RECOVER 2.0 Worksheet
2 QUESTION ID: ALS-19
3
PICO Question:
In cats and dogs with any cause of CPA (P) does any other atropine dosing interval (I) compared with atropine every 3-5 minutes (C) improve outcome (O)?
4
Outcomes:
Favorable neurologic outcome,Surrogate marker(s) of perfusion,Survival to Discharge,ROSC
5 Prioritized Outcomes (1= most critical; final number = least important):
- 6 Favorable neurologic outcome
- 7 Survival to discharge
- 8 ROSC
- 9 Surrogate markers of perfusion
10
Domain chairs: Gareth Buckley, Elizabeth Rozanski, Jake Wolf, final edits Dan Fletcher
11 Evidence evaluators: Nick Parkinson, Erin Binagia
12 Conflicts of interest: None
13 Search strategy: See attached document
|
14 Study Design |
15 Reduced Quality Factors
16 0 = no serious, - = serious,
17 - - = very serious |
18 Positive Quality Factors
19 0 = none, + = one, ++ = multiple |
20 Dichotomous Outcome Summary |
21 Non-Dichotomous Outcome Summary
22 Brief description |
23 Overall Quality
24
High, moderate, low, |
||||||||
|
25 No of studies |
26 Study Type |
27 RoB |
28 Indirectness |
29 Imprecision |
30 Inconsistency |
31 Large Effect |
32 Dose-Response |
33 Confounder |
34 # Intervention with Outcome |
35 # Control with Outcome |
36 RR (95% CI) |
|
|
|
37 Outcome: Favorable Neuro Outcome |
|||||||||||||
|
38 1 |
39 CT |
40 – |
41 - - |
42 – |
43 0 |
44 0 |
45 0 |
46 0 |
|
|
|
47 there was no significant difference in outcome |
48 Very low
|
|
49 Outcome: Survival to discharge |
|||||||||||||
|
50 1 |
51 CT |
52 – |
53 - - |
54 – |
55 0 |
56 0 |
57 0 |
58 0 |
|
|
|
59 there was no significant difference in outcome |
60 Very low
|
|
61 12 |
62 OB |
63 0 |
64 – |
65 – |
66 - |
67 0 |
68 0 |
69 0 |
|
|
|
70 Higher atropine doses associated with decreased survival to discharge |
71 Very low
|
|
72 1 |
73 ES |
74 0 |
75 – |
76 – |
77 - |
78 0 |
79 0 |
80 0 |
|
|
|
81 Higher doses of atropine associated with higher mortality |
82 Very low |
|
83 Outcome: ROSC |
|||||||||||||
|
84 1 |
85 CT |
86 – |
87 - - |
88 – |
89 0 |
90 0 |
91 0 |
92 0 |
|
|
|
93 there was no significant difference in outcome |
94 Very low
|
|
95 5 |
96 OB |
97 0 |
98 – |
99 - |
100 - |
101 0 |
102 0 |
103 0 |
|
|
|
104 Atropine may be associated with ROSC; repeat dosing not evaluated |
105 Very low |
|
106 1 |
107 ES |
108 0 |
109 – |
110 – |
111 - |
112 0 |
113 0 |
114 0 |
|
|
|
115 Higher doses of atropine associated with higher mortality |
116 Very low |
|
117 Outcome: Surrogate markers - no evidence |
118 PICO Question Summary
|
119 Introduction |
|
120 Veterinary guidelines state that one may consider atropine administration at a dosing interval of every 3-5 minutes during CPR in patients with non-shockable arrest rhythms.1 There have been little data in veterinary medicine to support a specific dosing interval. The recommendation for atropine administration during CPR was removed from human CPR guidelines in 2010.2
|
|
121 Consensus on science |
|
122 Outcome 1: Favorable Neurologic Outcome
123 For the most critical outcome of favorable neurologic outcome, one clinical trial was identified (very low quality of evidence, downgraded for serious risk of bias, very serious indirectness, and serious imprecision). A study of 7,448 adults by the SOS-KANTO Study Group (2011) showed that epinephrine and atropine administration together resulted similar 30 day neurological outcome as epinephrine alone.3
124 Outcomes 2 and 3: Survival to Hospital Discharge and ROSC
125 For the next most critical outcomes of survival to hospital discharge and ROSC, we identified 1 clinical trial (very low quality of evidence, downgraded for serious risk of bias, serious indirectness, and serious imprecision), 12 observational studies (downgraded for serious indirectness, serious imprecision, and serious inconsistency), and 1 experimental study (very low quality of evidence downgraded for very serious indirectness and imprecision).3–16 The clinical trial (adults with out-of-hospital cardiac arrest) and observational studies (5 in adults with out-of-hospital cardiac arrest, 1 in adults with in-hospital cardiac arrest, 1 in children with out-of-hospital cardiac arrest, and 5 in adults that either did not specify arrest location or included both in- and out-of-hospital cardiac arrest) were all in people. The experimental study was in mongrel dogs. Most studies evaluated the association of atropine administration with survival and did not specifically examine repeated atropine administration and its association with outcome.
126 Chang et al. (2005) found in a study of 361 adults with out-of-hospital arrest in Taiwan that lower atropine dose was positively associated with survival to discharge.7 Similarly, a study of 159 adults who underwent CPR at a hospital in Pakistan found that a higher total atropine dose was associated with decreased survival to discharge (OR 0.68, 95%CI = 0.47 – 0.99, P=0.05).9 Agreeing with these findings, Dumot et al. (2001) found in a study of 445 adults who received advanced life support during CPR that atropine use was associated (p<0.01) with poor survival to discharge and administration of any atropine during resuscitation cut the survival rate in half.10 Additional atropine doses resulted in survival to hospital discharge rates of less than 5%. In this study, the number of atropine ampules administered to survivors was a quarter of that administered to non-survivors (0.4 v. 1.7 ampules). A study of 7,448 adults by the SOS-KANTO Study Group (2011) showed that epinephrine and atropine administration together resulted in higher ROSC than epinephrine alone for adults with asystole, but a similar 30 day neurological outcome was noted.3 However, in adults with pulseless electrical activity, the epinephrine with atropine group had a significantly lower survival than those who received epinephrine alone (P=0.02). In a study of adults with both in-hospital and out-of-hospital cardiac arrest by Stiell et al. (1995), no association was noted between atropine administration and ROSC or survival to discharge.15 However, administration of atropine during the fourth quartile of CPR was associated with improved ROSC. Behnke et al. (1995) showed in an experimental study in 75 mongrel dogs with an asphyxial model of pulseless electrical activity that the standard dose of atropine did not improve ROSC or survival compared with placebo and that higher doses of atropine tended to decrease ROSC.16
|
|
127 Treatment recommendation |
|
128 We suggest against administering multiple doses of atropine (weak recommendation, very low quality of evidence).
|
|
129 Justification of treatment recommendation |
|
130 There is little evidence for administration of atropine in humans with CPA, which led to its removal from the 2010 American Heart Association’s Advanced Cardiac Life Support guidelines.2 There is even less information on dosing frequency or total dosage of atropine administration in humans, though some data suggest a higher dose of atropine is associated with decreased survival in people and dogs. In addition, although the pharmacokinetics of intravenous atropine in dogs and cats have not been well studied, there is evidence that at a dose of 0.03mg/kg IV, heart rate remains elevated in dogs for 30 minutes after administration.17 In humans, the half life of IV atropine is approximately 4 hours.18 This suggests that repeated doses of atropine in dogs and cats could result in excessive plasma concentrations, which could lead to detrimental effects on myocardial oxygen consumption in the PCA period. The applicability to dogs and cats with cardiopulmonary arrest, however, is unknown. Based on the findings in human medicine, we suggest a weak recommendation against repeated atropine administration during cardiopulmonary resuscitation in dogs and cats.
|
|
131 Knowledge gaps |
|
132 The appropriate dosing interval for atropine in dogs and cats in cardiopulmonary arrest is unknown. The necessity of atropine administration during cardiopulmonary arrest in dogs and cats is also unknown. It is unknown whether atropine administration and dosing during cardiopulmonary arrest should be based on the underlying disease process (e.g., arrests precipitated by increased vagal tone) or arrest rhythm.
|
133 References:
134 1. Fletcher DJ, Boller M, Brainard BM, et al. RECOVER evidence and knowledge gap analysis on veterinary CPR. Part 7: Clinical guidelines: RECOVER clinical guidelines. J Vet Emerg Crit Care. 2012;22(s1):S102-S131.
135 2. Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary. Circulation. 2010;122(18_suppl_3):S640-S656.
136 3. The Survey of Survivors After Out-of Hospital Cardiac Arrest. Atropine Sulfate for Patients With Out-of-Hospital Cardiac Arrest due to Asystole and Pulseless Electrical Activity. Circ J. 2011;75(3):580-588.
137 4. Coon GA, Clinton JE, Ruiz E. Use of atropine for brady-asystolic prehospital cardiac arrest. Ann Emerg Med. 1981;10(9):462-467.
138 5. Yano T, Kawana R, Yamauchi K, Endo G, Nagamine Y. The Additive Effect of Atropine Sulfate during Cardiopulmonary Resuscitation in Out-of-hospital Non-traumatic Cardiac Arrest Patients with Non-shockable Rhythm. Intern Med. 2019;58(12):1713-1721.
139 6. Robinson S, Swain AH, Hoyle SR, Larsen PD. Survival from out-of-hospital cardiac arrest in New Zealand following the 2005 resuscitation guideline changes. Resuscitation. 2010;81(12):1648-1651.
140 7. Chang MY, Lin M. Predictors of survival and hospital outcome of prehospital cardiac arrest in southern Taiwan. J Formos Med Assoc. 2005;104(9):639-646.
141 8. Erenler AK, Çelik S, Baydin A, et al. Outcomes of cardiopulmonary resuscitation in trauma patients in the Emergency Department. Eur Rev Med Pharmacol Sci. 2015;19(14):2567-2571.
142 9. Ishtiaq O, Iqbal M, Zubair M, Qayyum R, Adil M. Outcome of cardiopulmonary resuscitation - predictors of survival. J Coll Physicians Surg Pak. 2008;18(1):3-7.
143 10. Dumot JA, Burval DJ, Sprung J, et al. Outcome of adult cardiopulmonary resuscitations at a tertiary referral center including results of “limited” resuscitations. Arch Intern Med. 2001;161(14):1751-1758.
144 11. Moler FW, Donaldson AE, Meert K, et al. Multicenter cohort study of out-of-hospital pediatric cardiac arrest. Crit Care Med. 2011;39(1):141-149.
145 12. Holmberg MJ, Moskowitz A, Wiberg S, et al. Guideline removal of atropine and survival after adult in-hospital cardiac arrest with a non-shockable rhythm. Resuscitation. 2019;137:69-77.
146 13. Herlitz J, Bång A, Gunnarsson J, et al. Factors associated with survival to hospital discharge among patients hospitalised alive after out of hospital cardiac arrest: change in outcome over 20 years in the community of Göteborg, Sweden. Heart. 2003;89(1):25-30.
147 14. van Walraven C, Stiell IG, Wells GA, Hébert PC, Vandemheen K. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC Study Group. Ann Emerg Med. 1998;32(5):544-553.
148 15. Stiell IG, Wells GA, Hebert PC, Laupacis A, Weitzman BN. Association of Drug Therapy with Survival in Cardiac Arrest: Limited Role of Advanced Cardiac Life Support Drugs. Acad Emerg Med. 1995;2(4):264-273.
149 16. Behnke DJD, Swart GL, Spreng D, Aufderheide TP. Standard and Higher Doses of Atropine in a Canine Model of Pulse less Electrical Activity. Acad Emerg Med. 1995;2(12):1034-1041.
150 17. Hendrix PK, Robinson E p. Effects of a selective and a nonselective muscarinic cholinergic antagonist on heart rate and intestinal motility in dogs. J Vet Pharmacol Ther. 1997;20(5):387-395.
151 18. Adams RG, Verma P, Jackson AJ, Miller RL. Plasma Pharmacokinetics of Intravenously Administered Atropine in Normal Human Subjects. J Clin Pharmacol. 1982;22(10):477-481.
152 Supplemental:
153 Outcome: Favorable neurologic outcome
154 0 Clinical Trials
155 0 Observational Studies
156 0 Experimental Studies
157 Outcome: Survival to Discharge
158 1 Clinical Trials
159 Coon et al (1981): Use of atropine for brady-asystolic prehospital cardiac arrest
160 ● Prospective study in which people with PEA or asystole were either administered atropine (1 mg initially, repeated in 1 minute if no rhythm change) or non-atropine
161 ● Not blinded, no placebo, the control group could receive calcium, steroid, isoproterenol, bicarbonate and atropine whereas study group received these only after atropine administration (all did receive initial dose of epinephrine and bicarbonate)
162 ● Only 21 patients enrolled, only one patient survived to discharge
163 ● Atropine made no difference in survival
164 12 Observational Studies
165 Yano et al (2019): The Additive Effect of Atropine Sulfate during Cardiopulmonary Resuscitation in Out-of-hospital Non-traumatic Cardiac Arrest Patients with Non-shockable Rhythm
166 ● Retrospective observational study of patients over 5 year period
167 ● Addition of atropine following epinephrine increased OR for survival to hospital admission for PEA and asystole when compared to epinephrine alone. However, only one patient had a good neuro outcome and 11 patients were alive and therefore binomial multivariate logistic regression analysis was not possible for 30 day survival or good 30 day neuro outcome
168 ● More similar to atropine v. no atropine though repeat dosing was allowed and its inclusion up to 2 mg was potentially associated with predictor of survival to hospital admission
169 Robinson et al (2010): Survival from OHOCA in NZ following the 2005 resuscitation guideline changes
170 ● Retrospective comparative study on OOHCA in NZ after removal of atropine for guidelines for CPR
171 ● No significant difference in survival to hospital discharge following the change (increase in those who achieved ROSC)
172 ● Improved survival to hospital admission but not to discharge
173 Chang et al (2005): Predictors of Survival and hospital outcome of prehospital cardiac arrest in southern Taiwan
174 ● Retrospective review of OOHCA
175 ● Lower atropine dose associated with survival to discharge
176 Erenler et al (2015): Outcomes of CPR in trauma patients in the ED
177 ● Retrospective collection of data from trauma patients who required CPR
178 ● No difference in survival with atropine administration
179 Ishtiaq et al (2008): Outcome of CPR - Predictors of survival
180 ● All adult patients who underwent CPR in Pakistan
181 ● Total atropine dose associated with decreased survival to discharge (p=0.05) during univariate logistic regression analysis
182 ● Only 17 patients discharged alive from hospital
183 Duomo et al (2001): Outcome of adult CPR at a tertiary referral center including results of limited resuscitations
184 ● Statistical analysis of 445 prospectively recorded resuscitation records of patients who received ALS
185 ● Atropine use associated with poor immediate and hospital discharge survival on multivariate analysis (p<0.01)
186 ● Administration of any atropine during resuscitation cut survival rate in half
187 ● Additional atropine doses resulted in survival to hospital discharge of less than 5%
188 Moler et al (2011): Multicenter cohort study of OOH pediatric cardiac arrest
189 ● retrospective cohort study at 15 clinical sites
190 ● Multivariate analysis: administration of atropine associated with mortality
191 ● No discussion about repeated dosages
192 Holmberg et al (2019): Guideline removal of atropine and survival after adult in-hospital cardiac arrest with non-shockable rhythm
193 ● adults with in hospital cardiac arrest between 2006-2015 and asystole or PEA
194 ● No change in survival after removal of atropine from guidelines in 2010
195 Herlitz et al (2003): Factors associated with survival to hospital discharge among patients hospitalized alive after OOHCA
196 ● Retrospective analysis of prospectively recorded patient data in Sweden who experienced OOHCA
197 ● Those who “required” atropine in the ED had a lower survival (p<0.01) in multivariate analysis
198 van Walraven et al (1998): Do Advanced cardiac life support drugs increase resuscitation rates from IHCA?
199 ● Prospective cohort of patients undergoing cardiac arrest in hospital
200 ● At 1 hour after survival, administration of atropine was associated with higher mortality (including when controlling for arrest rhythm; p<0.01)
201 SOS-KANTO Study Group (2011): Atropine sulfate for patients with OOHCA due to asystole and PEA
202 ● Retrospective review of SOS-Kanto study
203 ● Epi with atropine had significantly higher ROSC than epi alone, but similar 30 day neuro outcome. In PEA, the epi with atropine group had significantly lower 30 day survival than epi alone (p=0.02)
204 Stiell et al (1995): Association of drug therapy with survival in cardiac arrest
205 ● Observational cohort study in two tertiary hospitals of adults who suffered either in or OOH cardiac arrest
206 ● Univariate analysis revealed no association between atropine administration and resuscitation or discharge
207 ● Administration of atropine during the fourth quartile of CPR was associated with initial resuscitation
208 1 Experimental Studies
209 Behnke et al (1995): Standard and Higher Doses of atropine in a canine model of PEA
210 ● Experimental study in mongrel dogs in which asphyxial model of PEA created (75 dogs untreated PEA for 10 minutes)
211 ● Randomized to receive placebo and one of four doses of atropine (single dose)
212 ● All received mechanical external CPR and epinephrine every 3 minutes
213 ● Standard dose atropine did not improve ROSC compared with placebo and increasing doses tended to decrease ROSC
214 Outcome: ROSC
215 1 Clinical Trials
216 Coon et al (1981): Use of atropine for brady-asystolic prehospital cardiac arrest
217 ● Prospective study in which people with PEA or asystole were either administered atropine (1 mg initially, repeated in 1 minute if no rhythm change) or non-atropine
218 ● Not blinded, no placebo, the control group could receive calcium, steroid, isoproterenol, bicarbonate and atropine whereas study group received these only after atropine administration (all did receive initial dose of epinephrine and bicarbonate)
219 ● Only 21 patients enrolled, only one patient survived to discharge
220 ● Atropine made no difference in survival
221 5 Observational Studies
222 Holmberg et al (2019): Guideline removal of atropine and survival after adult in-hospital cardiac arrest with non-shockable rhythm
223 ● adults with in hospital cardiac arrest between 2006-2015 and asystole or PEA
224 ● No change in ROSC after removal of atropine from guidelines in 2010
225 1 Experimental Studies
226 Behnke et al (1995): Standard and Higher Doses of atropine in a canine model of PEA
227 ● Experimental study in mongrel dogs in which asphyxial model of PEA created (75 dogs untreated PEA for 10 minutes)
228 ● Randomized to receive placebo and one of four doses of atropine (single dose)
229 ● All received mechanical external CPR and epinephrine every 3 minutes
230 ● Standard dose atropine did not improve ROSC compared with placebo and increasing doses tended to decrease ROSC
231 Robinson et al (2010): Survival from OHOCA in NZ following the 2005 resuscitation guideline changes
232 ● Retrospective comparative study on OOHCA in NZ after removal of atropine for guidelines for CPR
233 ● Trend towards higher ROSC without atropine use
234 Vanags et al (1989): Interventions in the therapy of electromechanical dissociation
235 ● Adults with non-traumatic non-poisoning CPA with initial rhythm of EMD
236 ● Atropine administered to 22% of patients
237 ● Atropine associated with attainment of a pulse in EMD
238 SOS-KANTO Study Group (2011): Atropine sulfate for patients with OOHCA due to asystole and PEA
239 ● Retrospective review of SOS-Kanto study
240 ● Multivariate analysis showed that administration of atropine was independent predictor of ROSC with asystole but not with PEA
241 Stiell et al (1995): Association of drug therapy with survival in cardiac arrest
242 ● Observational cohort study in two tertiary hospitals of adults who suffered either in or OOH cardiac arrest
243 ● Univariate analysis revealed no association between atropine administration and resuscitation or discharge
244 ● Administration of atropine during the fourth quartile of CPR was associated with initial resuscitation
245 Outcome: Surrogate markers of perfusion
246 0 Clinical Trials
247 0 Observational Studies
248 0 Experimental Studies
icons on the left to see existing comments.
0 archived comments